GC012F (AZD0120)
A Phase 1 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Early-Line Treatment in Subjects With Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 20 patients (estimated)
- Sponsors
- AstraZeneca
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA), CD19, High Risk, Monotherapy, Open Label, Single Cohort
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 2146
- NCT Identifier
- NCT07073547
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.